| 2014 | 2015 | 2016 | 2017 | AAPC (%) |
---|---|---|---|---|---|
Polysubstance | |||||
 Both sexes | |||||
  n | 868 | 1052 | 1477 | 2352 |  |
  Rate | 2.45 | 2.95 | 4.09 | 6.44 | 40.5* |
  95 % CI | (2.29, 2.61) | (2.77, 3.13) | (3.88, 4.30) | (6.18, 6.70) | (17.5, 67.9) |
 Males | |||||
  n | 583 | 750 | 1045 | 1776 |  |
  Rate | 3.32 | 4.23 | 5.83 | 9.80 | 45.9* |
  95 % CI | (3.05, 3.58) | (3.93, 4.54) | (5.48, 6.19) | (9.35, 10.26) | (20.2, 77.1) |
 Females | |||||
  n | 285 | 302 | 432 | 576 |  |
  Rate | 1.60 | 1.68 | 2.38 | 3.13 | 27.6* |
  95 % CI | (1.41, 1.78) | (1.49, 1.87) | (2.15, 2.60) | (2.87, 3.38) | (7.9, 50.8) |
Single substance | |||||
 Both sexes | |||||
  n | 1413 | 1346 | 1541 | 1860 |  |
  Rate | 3.99 | 3.77 | 4.27 | 5.10 | 9.3 |
  95 % CI | (3.78, 4.19) | (3.57, 3.97) | (4.06, 4.48) | (4.86, 5.33) | (-6.5, 27.9) |
 Males | |||||
  n | 945 | 912 | 1088 | 1338 |  |
  Rate | 5.37 | 5.15 | 6.07 | 7.39 | 12.3 |
  95 % CI | (5.03, 5.72) | (4.82, 5.48) | (5.71, 7.77) | (6.99, 7.78) | (-4.5, 32.1) |
 Females | |||||
  n | 468 | 433 | 453 | 522 |  |
  Rate | 2.62 | 2.41 | 2.49 | 2.84 | 2.9 |
  95 % CI | (2.38, 2.86) | (2.18, 2.64) | (2.26, 2.72) | (3.08, 2.59) | (-10.7, 18.6) |